Grassroots Marketing speaks with Whitney Conroy (Chief Commercial Officer) and Alisha Holloway, PhD, Chief Scientific Officer at Phylos. We discuss a collaboration with People Science on recently announced groundbreaking findings from an IRB-approved, double-blind clinical study. This study throws light on the effects of the rare cannabinoid tetrahydrocannabivarin (THCV), particularly highlighting the Natural Natural TM variant's ability to significantly elevate energy, activity, motivation, and well-being without the typical fatigue and hunger associated with THC.

Alisha shares her involvement with a group advocating science-backed legalization materials, noting DEA pushback on rescheduling due to high THC levels. Varying strengths of antibiotics are compared, discussing purposes. We also discuss the recent headlines stemming from a New York Times article mentioning federal scientists' findings on cannabis safety and non-addictiveness, highlighting legalization's pivot on lobbying and Congress supermajorities for policy changes.

Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy